Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VYD2311 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| VYD2311 | EXPERIMENTAL | Injection in healthy volunteer |
| Placebo | PLACEBO_COMPARATOR | Injection in healthy volunteer |
| Name | Type | Description |
|---|---|---|
| VYD2311 | BIOLOGICAL | Monoclonal antibody |
| Placebo | OTHER | Matching Placebo |
Inclusion Criteria: * Is a male or female participant aged 18 to 65 years, inclusive. * Has a body mass index 18.0 to 32.0 kg/m2, inclusive. * Is in good health, with no clinically significant abnormalities as determined by the Investigator based on medical history, physical exam, vital signs, ECG,...
VYD2311 is an investigational monoclonal antibody being developed for COVID-19. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied for its potential to prevent or treat COVID-19, though its exact use is still under investigation.
VYD2311 is a monoclonal antibody designed to target SARS-CoV-2, the virus that causes COVID-19. As an antibody, it is intended to bind to the virus and neutralize it, potentially reducing the severity of infection. However, the specific viral protein it targets has not been disclosed.
VYD2311 is being developed by Invivyd, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol IVVD. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational monoclonal antibody for COVID-19.
VYD2311 is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The Phase 1 trial is designed to assess the safety, tolerability, and pharmacokinetics of the drug in healthy participants.
VYD2311 is being evaluated in a Phase 1 clinical trial with the identifier NCT06523153. This randomized, double-blind, placebo-controlled study is enrolling 40 healthy participants in Australia. The trial is active but not currently recruiting, and it is designed to assess the safety and tolerability of VYD2311.
VYD2311 is a distinct investigational monoclonal antibody developed by Invivyd, Inc. There are no alternative names provided for this drug. It is not the same as any other approved or investigational drug, and it is being studied specifically for its potential use in COVID-19.